Key result
Initiating an IV cangrelor infusion prior to stenting with a post-PCI transition to oral ticagrelor is proposed to provide optimal protection against infarction and minimize bleeding risks.
Why the study?
Does initiating IV cangrelor prior to stenting followed by transition to oral ticagrelor optimize outcomes in patients with acute coronary syndrome?
Does initiating IV cangrelor prior to stenting followed by transition to oral ticagrelor optimize outcomes in patients with acute coronary syndrome?
Answers are grounded in this paper and cite their sources.
The authors suggest that an IV cangrelor infusion prior to stenting followed by transition to oral ticagrelor provides optimal protection against infarction while minimizing bleeding risk if CABG is needed.
level of inhibition by the time of balloon inflation. However, optimal treatment could be assured by initiating an IV cangrelor infusion shortly prior to stenting followed by subsequent post-PCI transition to an oral agent, that is, ticagrelor, once success of the recanalization and absence of need for surgical intervention are confirmed. Not only should this sequence provide optimal protection against infarction, it should also negate bleeding if coronary artery bypass grafting should be required since stopping the cangrelor infusion at any time will quickly restore platelet reactivity. It is anticipated that cangrelor-induced myocardial salvage will help preserve myocardial function and significantly diminish postinfarction heart failure.
No takes yet. Share an insight, caveat, or question.
Cohen et al. (2019) conducted an editorial in Acute Coronary Syndrome. IV cangrelor followed by oral ticagrelor was evaluated. Initiating an IV cangrelor infusion prior to stenting with a post-PCI transition to oral ticagrelor is proposed to provide optimal protection against infarction and minimize bleeding risks.
Synapse has enriched 10 related papers. Consider them for comparative context: